PIGMENT – PDE6A gene therapy for retinitis pigmentosa

2024-517924-20-00 Protocol RDC-PDE6A-01 Phase I and Phase II (Integrated) - First administration to humans Ongoing, recruitment ended

Start 24 Sep 2019 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 1 sites · Protocol RDC-PDE6A-01

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - First administration to humans
Status Ongoing, recruitment ended
Participants planned 9
Countries 1
Sites 1

PDE6A-linked Retinitis Pigmentosa

Key facts

Sponsor
Universitaetsklinikum Tuebingen AöR
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Eye Diseases [C11]
Trial duration
24 Sep 2019 → ongoing
Decision date (initial)
2024-09-24
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-517924-20-00
EudraCT number
2016-003705-34

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

PDE6A-linked Retinitis Pigmentosa

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Universitaetsklinikum Tuebingen AöR

Sponsor organisation
Universitaetsklinikum Tuebingen AöR
Address
Geissweg 3, Innenstadt Innenstadt
City
Tuebingen
Postcode
72076
Country
Germany

Scientific contact point

Organisation
Universitaetsklinikum Tuebingen AöR
Contact name
STZ eyetrial

Public contact point

Organisation
Universitaetsklinikum Tuebingen AöR
Contact name
STZ eyetrial

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruitment ended 9 1
Rest of world 0

Investigational sites

Germany

1 site · Ongoing, recruitment ended
Universitaetsklinikum Tuebingen AöR
Centre for Ophthalmology, University Tübingen, Elfriede-Aulhorn-Strasse 7, Nordstadt, Tuebingen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2019-09-24 2019-09-25 2021-07-07

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-10 Germany Acceptable
2024-09-19
2024-09-24
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-07-17 Germany Acceptable
2024-09-19
2025-07-17